Multi-omics Mass Spectrometry and Biomarker Discovery Core

多组学质谱和生物标志物发现核心设施共享资源 摘要 多组学质谱和生物标志物发现核心设施（MMSBD）提供癌症中心 (CC)成员与质谱（MS）为基础的多组学技术，以支持癌症研究 发病机制、癌症生物标志物、新型抗癌剂和诊断研究。多组学方法 所提供的服务包括蛋白质组学、肽组学、糖组学、脂质组学、代谢组学 和小分子分析。定量磷酸化蛋白质组学和深度蛋白质组学是提供的新服务 在目前的融资期内。核心从项目构思到执行提供科学的咨询 准备手稿和赠款申请。 主要核心服务包括：1）液相色谱/质谱（LC/MS）; 2）非靶向/靶向 蛋白质组学，包括无标记定量蛋白质组学以及同量异位素串联稳定同位素标记 培养物中氨基酸的质量标签或稳定同位素标记; 3）后- 翻译修饰; 4）从头肽/蛋白质序列分析; 5）在翻译修饰下的肽序列验证。 GMP条件（核心是FDA注册的）; 6）脂质组学和代谢组学; 7）生物标志物发现， 临床样品; 8）小分子、肽、药物的测定开发和定量，以及 潜在的生物标志物; 9）通过MALDI-MS的组织生物标志物分析;和10）组织成像质谱。 MMSBD配备了尖端的主要仪器，包括轨道阱融合Tribrid质量 质谱仪（Thermo）; 6490三重四极杆质谱仪（Agilent）;几个LC Q-TOF质谱仪; 质谱仪（沃茨和Agilent）和两个MALDI-MS仪器。第二个高端轨道阱质量 正在购买光谱仪（Fusion Lumos; Thermo），以满足对LC/MS仪器日益增长的需求 时间数据分析是在核心维护的工作站和多节点计算机集群上进行的， 同时运行商业和开源软件。软件不断更新，MS和元数据 自动备份并存储在位于主园区内外的多个冗余存储单元上。 核心由Markus Kalkum博士和Robert Hickey博士共同指导，他们都是Beckman的教师 研究院影响核心预算的关键决定由一个咨询委员会审查， 使用核心服务的成员。自上次竞争性续约以来，MMSBD贡献了26 出版物，并为73名调查员提供服务，其中52人是代表所有五个 程序.在52个协调委员会成员中，45个（87%）有同行评审的资金。因此，MMSBD提供 可访问的，具有成本效益的，高质量的多组学质谱和生物标志物发现服务， 支持希望之城综合癌症中心的研究。

Multi-omics Mass Spectrometry & Biomarker Discovery Core Facility Shared Resource ABSTRACT The Multi-omics Mass Spectrometry & Biomarker Discovery Core Facility (MMSBD) provides Cancer Center (CC) members with mass spectrometry (MS)-based multi-omics technology to support research on cancer pathogenesis, cancer biomarkers, novel anti-cancer agents, and diagnostic studies. The multi-omics approaches provided encompass high-quality MS services for proteomics, peptidomics, glycomics, lipidomics, metabolomics, and small molecule analyses. Quantitative phosphoproteomics and deep proteomics are new services provided during the current funding period. The Core offers scientific consultation from project conception and execution to preparation of manuscripts and grant applications. Primary Core services are: 1) liquid chromatographic/mass spectrometry (LC/MS); 2) untargeted/targeted proteomics, including label-free quantitative proteomics as well as stable isotope labeling with isobaric tandem mass tags or stable isotope labeling of amino acids in culture; 3) identification and quantification of post- translational modifications; 4) de novo peptide/protein sequence analysis; 5) peptide sequence validation under GMP conditions (the Core is FDA-registered); 6) lipidomics and metabolomics; 7) biomarker discovery from clinical samples; 8) assay development and quantification of small molecules, peptides, drugs, and validation of potential biomarkers; 9) tissue biomarker profiling by MALDI-MS; and 10) tissue imaging mass spectrometry. The MMSBD is well equipped with cutting-edge major instrumentation including an Orbitrap Fusion Tribrid mass spectrometer (Thermo); a 6490 Triple Quadrupole mass spectrometer (Agilent); several LC Q-TOF mass spectrometers (Waters and Agilent), and two MALDI-MS instruments. A second high-end Orbitrap mass spectrometer (a Fusion Lumos; Thermo) is being purchased to meet increased demands for LC/MS instrument time. Data analyses are performed on Core-maintained workstations and multi-node computer clusters that operate both commercial and open source software. Software is constantly updated and MS and metadata are automatically backed up and stored on several redundant storage units located on and off the main campus. The core is co-directed by Drs. Markus Kalkum and Robert Hickey, who are both faculty within Beckman Research Institute. Key decisions affecting the Core are reviewed by an Advisory Committee, composed of CC members who use the Core’s services. Since the last competitive renewal, the MMSBD contributed to 26 publications by CC members and served 73 investigators, 52 of whom were CC members representing all five Programs. Of the 52 CC members, 45 (87%) had peer-reviewed funding. Accordingly, the MMSBD provides accessible, cost-effective, and high-quality multi-omics mass spectrometry and biomarker discovery services to support the research of the City of Hope Comprehensive Cancer Center.